BRISBANE, Calif., Oct. 22 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that key data supporting its PARP (poly-ADP-ribose polymerase) inhibitor drug development programs will be presented at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics in San Francisco from Oct. 22 to 26 and the EORTC-NCI-ASCO Annual Meeting on “Molecular Markers in Cancer” in Brussels, Nov. 15 to 17.
PARP is a novel, validated target for cancer treatment. PARP1 plays a central role in cell proliferation and in DNA repair. BiPar scientists will present results showing that PARP1 gene expression is significantly upregulated in many but not all tumor types. BiPar’s novel, proprietary PARP inhibitors are members of a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinical studies suggest the drugs selectively inhibit tumor cell proliferation and are active against a broad range of tumor types. BiPar is initiating Phase 1b and Phase 2 clinical trials of BSI-201, its lead PARP inhibitor, in several major cancers. That research program has been directed in large part by the molecular biomarker data being presented at these meetings.
“These findings will focus our efforts on those tumor types with the greatest opportunity for clinical success,” said Barry Sherman, M.D., BiPar’s executive vice president. “With this information we believe we will be able to efficiently exploit our pipeline of PARP inhibitors that target major unmet needs in cancer.”
About BiPar Sciences
BiPar Sciences Inc. (http://www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a pipeline of novel, tumor-selective drugs designed to meet the significant unmet needs of cancer patients.
CONTACT: Eric Malek, Vice President of Corporate Development of BiPar
Sciences, +1-650-635-0165, emalek@biparsciences.com; or Brian Reid of
WeissComm Partners, +1-703-402-3626, breid@weisscommpartners.com for BiPar
Sciences
Web site: http://www.biparsciences.com/
